Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age and signed written informed consent~* Patients scheduled to undergo major orthopaedic surgery (hip or knee arthroplasty or back surgery)~* 10 g/dl \< Hb \< 13.0 g/dl for men and 10 g/dl \< Hb \< 12.0 g/dl for women, at screening ( 3 weeks prior to surgery)~* Ferritin \< 100 μg/l or 100-300 with TSat \< 20%~Exclusion Criteria:~* Suspicion of iron overload (Ferritin \>300 μg/l or/and TSAT\>50%)~* Active severe infection/inflammation (defined as serum CRP \> 20 mg/l) or diagnosed malignancy~* Folate-and/or Vitamin B12 deficiency (according to local lab reference range)~* Known history of hepatitis B/C or HIV-positive~* Liver values 3 times higher than normal~* Immunosuppressive or myelosuppressive therapy~* A concurrent medical condition(s) that, in the view of the investigator, would prevent compliance or participation or jeopardize the health of the patients.~* Pregnancy or lactation~* Transfusion within 1 month prior to study inclusion, EPO treatment with in the last 4 weeks, any iron treatment within 4 weeks prior to the inclusion in the trail~* Participation in any other therapeutic trial within the previous month~* History of thromboembolic events in the family or the patient~* Severe peripheral, coronary or carotid artery disease~* Bodyweight \< 50 kg~* Patients not able to understand the German language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo for EPO and for Ferinject ®
- 2 (Type: ACTIVE_COMPARATOR): Only Ferinject ® , Placebo for EPO
- 3 (Type: ACTIVE_COMPARATOR): Ferinject ® + EPO

Based on this trial design, predict the completion outcome and termination type (if applicable).